Grant boost for Oxford's Glox Therapeutics

 

Oxford spin out Glox Therapeutics has secured £1m in grant funding

 

The money has been awarded by PACE (Pathways to Antimicrobial Clinical Efficacy), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.

 

Glox Therapeutics pioneer the development of precision antibiotic therapies based on naturally occurring bacteriocins,

 

The company, established in February 2023, is a biotechnology company focused on developing precision antibiotics to combat antimicrobial resistance (AMR).

 

It  was co-founded by Professor Daniel Walker from the University of Glasgow (now at the University of Strathclyde) and Professor Colin Kleanthous from the University of Oxford, both experts in bacteriocin research.

 

The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli and Klebsiella pneumoniae. It will also enable the company to expand its team and foster further collaboration with industry experts.

 

Dr James Clark, CEO and Co-founder, Glox Therapeutics, said: “We are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology. Glox Therapeutics is one of only a handful of companies to have been selected for PACE funding so far which is a true testament to the expertise of our world-leading team."